Patents by Inventor Qui-Lim Choo
Qui-Lim Choo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6096541Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: May 15, 1995Date of Patent: August 1, 2000Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 6074852Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: GrantFiled: May 17, 1995Date of Patent: June 13, 2000Assignee: Chiron CorporationInventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 6074816Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: September 16, 1994Date of Patent: June 13, 2000Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 6027729Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: May 15, 1995Date of Patent: February 22, 2000Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5989905Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg.sup.2+ and Mn.sup.2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.Type: GrantFiled: April 8, 1997Date of Patent: November 23, 1999Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
-
Patent number: 5942234Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: GrantFiled: May 17, 1995Date of Patent: August 24, 1999Assignee: Chiron CorporationInventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 5932219Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: May 25, 1995Date of Patent: August 3, 1999Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
-
Patent number: 5885799Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.Type: GrantFiled: September 6, 1996Date of Patent: March 23, 1999Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5863719Abstract: A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. Reagents for isolating, amplifying, and detecting HCV polynucleotides are provided. These reagents are oligomers containing polynucleotide sequences which are capable of forming hybrid structures with HCV target polynucleotide sequences.Type: GrantFiled: June 7, 1995Date of Patent: January 26, 1999Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5750350Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA Of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta. of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: May 24, 1995Date of Patent: May 12, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
-
Patent number: 5747044Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: May 24, 1995Date of Patent: May 5, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
-
Patent number: 5714596Abstract: A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. Reagents for isolating, amplifying, and detecting HCV polynucleotides are provided. These reagents are oligomers comprised of polynucleotide sequences which are capable of forming hybrid structures with HCV target polynucleotide sequences.Type: GrantFiled: March 31, 1993Date of Patent: February 3, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo, Amy J. Weiner, Jang Han, Michael Steven Urdea, Bruce Duncan Irvine, Janice A. Kolberg
-
Patent number: 5712145Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.Type: GrantFiled: September 6, 1996Date of Patent: January 27, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5712087Abstract: Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.Type: GrantFiled: May 12, 1995Date of Patent: January 27, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5712088Abstract: A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. Reagents for isolating, amplifying, and detecting HCV polynucleotides are provided. These reagents are oligomers containing polynucleotide sequences which are capable of forming hybrid structures with HCV target polynucleotide sequences.Type: GrantFiled: May 15, 1995Date of Patent: January 27, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo, Amy J. Weiner, Jang Han, Michael Steven Urdea, Bruce Duncan Irvine, Janice A. Kolberg
-
Patent number: 5698390Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: September 15, 1994Date of Patent: December 16, 1997Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5683864Abstract: Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.Type: GrantFiled: July 7, 1992Date of Patent: November 4, 1997Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5597691Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.Type: GrantFiled: May 12, 1995Date of Patent: January 28, 1997Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5585258Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.Type: GrantFiled: December 6, 1994Date of Patent: December 17, 1996Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 5389528Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: July 27, 1993Date of Patent: February 14, 1995Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy J. Weiner, Lacy R. Overby